What is the recommended tirzepatide dosing schedule, including initiation dose and titration increments?

Tirzepatide Dosing

Tirzepatide is initiated at 2.5 mg subcutaneously once weekly for 4 weeks, then escalated by 2.5 mg every 4 weeks until the target maintenance dose is reached, with FDA-approved doses of 5 mg, 10 mg, and 15 mg weekly. 1

Standard Titration Schedule

The FDA-approved titration protocol follows a stepwise escalation:

• Weeks 1–4: 2.5 mg subcutaneously once weekly 1, 2, 3
• Weeks 5–8: 5 mg once weekly 1, 2, 3
• Weeks 9–12: 7.5 mg once weekly (optional intermediate step) 2
• Weeks 13–16: 10 mg once weekly 1, 2, 3
• Weeks 17–20: 12.5 mg once weekly (optional intermediate step) 2
• Week 21 onward: 15 mg once weekly (maximum approved dose) 1, 2, 3

The 4-week interval between dose escalations is critical to minimize gastrointestinal adverse events, which typically resolve within 4–8 weeks at each dose level. 1, 2, 3

Maintenance Dosing

The standard maintenance dose is 5 mg weekly, with escalation to 10 mg or 15 mg based on glycemic response and tolerability. 1, 4, 5

For type 2 diabetes management, the 10 mg dose produces HbA1c reductions of approximately 2.2% from baseline, while the 15 mg dose achieves reductions of 2.4%. 4, 5

For obesity management, the 15 mg dose achieves mean weight loss of 20.9% at 72 weeks, representing the most effective pharmacologic option currently available. 1

Alternative Titration Regimens

Three dose-escalation strategies have been studied, with slower titration associated with better gastrointestinal tolerability:

1. Standard escalation: 2.5 mg (weeks 0–3) → 5 mg (weeks 4–7) → 10 mg (weeks 8–11) → 15 mg (weeks 12+) 2
2. Rapid escalation: 4 mg (weeks 0–3) → 8 mg (weeks 4–7) → 12 mg (weeks 8–11) 2
3. Modified escalation: 2.5 mg (weeks 0–1) → 5 mg (weeks 2–3) → 10 mg (weeks 4–7) → 15 mg (weeks 8–11) 2

Lower starting doses (2.5 mg) and smaller increments are associated with reduced nausea incidence compared to more aggressive titration. 2

Administration Details

Tirzepatide is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm, on the same day each week, independent of meals. 1

The injection day may be shifted provided at least 48 hours (2 days) separate consecutive doses. 1

Missed Dose Management

If ≤4 days have elapsed since the missed dose, administer as soon as possible and resume the regular weekly schedule. 1

If >4 days have elapsed, skip the missed dose and administer the next dose on the originally scheduled day. 1

If 2 consecutive doses are missed, resume at the same dose if previously tolerated; if ≥3 consecutive doses are missed, restart the titration schedule beginning at 5 mg weekly. 1

Concomitant Medication Adjustments

When initiating tirzepatide in patients on insulin, reduce basal insulin by 20% immediately to prevent hypoglycemia. 1

For patients with HbA1c <8%, consider a more aggressive 30% insulin reduction. 1

Discontinue sulfonylureas entirely or reduce the dose by 50% before starting tirzepatide to minimize hypoglycemia risk. 1

Stop all DPP-4 inhibitors before initiating tirzepatide, as concurrent use provides no additional benefit. 1

Renal Dosing

No dose adjustment is required for tirzepatide across all stages of chronic kidney disease, including eGFR <30 mL/min/1.73 m² and end-stage renal disease. 1

Monitoring Requirements

Assess patients every 4 weeks during dose escalation for gastrointestinal tolerance, weight loss progress, blood pressure, and signs of pancreatitis or gallbladder disease. 1

Re-measure HbA1c at 12–16 weeks after reaching the therapeutic dose to determine efficacy; discontinue if weight loss is <5% after 3 months on a therapeutic dose. 1

Safety Considerations

Gastrointestinal adverse events (nausea 17–22%, diarrhea 13–16%, vomiting 6–10%) are dose-dependent and typically mild-to-moderate, decreasing over time with continued exposure. 1, 4, 5

Hypoglycemia risk is minimal when tirzepatide is used as monotherapy (0.6–1.7% incidence), but increases when combined with insulin or sulfonylureas. 1

Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). 1

Special Populations

During Ramadan fasting, tirzepatide 2.5 mg weekly demonstrated significant improvements in glycemic control (HbA1c reduction of 1.1%) and body weight (mean reduction 5.3 kg) with no reported hypoglycemia. 6

For Japanese patients with type 2 diabetes, the same titration schedule (2.5 mg → 5 mg → 10 mg → 15 mg) was well tolerated, with a plasma half-life of approximately 5 days supporting once-weekly dosing. 3